Dear Client,
As part of our ongoing commitment to ensuring the security of your online trading experience, we would like to inform you of our protocol for addressing any suspicious activities observed on your trading account
Should you notice any irregularities or suspect unauthorized access to your account, we kindly request that you take immediate action by following the steps outlined below:
Send an Email Please send an email to stoptrade@acml.in from your registered email ID. In the email, briefly outline the suspicious activity you have observed.
Phone Call Alternatively, you can call us at 07968101000 Ext: 1 from your registered mobile number. This will enable us to address your concerns promptly.
When contacting us, please ensure you provide the following details:
By providing this information, you enable us to swiftly investigate and take appropriate measures to safeguard your account.
Your security and peace of mind are of utmost importance to us, and we appreciate your cooperation in maintaining the integrity of your trading account.
The company has launched Perampil, at 2 mg - Rs 49/strip of 7 tablets, 4 mg - Rs. 180/strip of 15 tablets and 6 mg - Rs. 300/strip of 15 tablets.
This product reaffirms Alkem's commitment towards improving epilepsy care by bringing multiple treatment options of quality products to patients and health care professionals in India. Alkem had also launched Brivasure (Brivaracetam) tablets in March 2021 for the adjunctive management of partial onset seizure with or without secondary generalization.
The drug, Perampanel, has been approved by the Drugs Controller General of India (DCGI), as an adjunctive therapy in treatment of partial onset seizures in patients with epilepsy aged 4 years and older and also as an adjunctive therapy in treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older.
Alkem is a pharmaceutical company with global operations. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and International markets.
On a consolidated basis, the company reported 27.1% increase in net profit to Rs 240 crore on 7% increase in revenue from operations to Rs 2192.2 crore in Q4 FY21 over Q4 FY20.
Powered by Capital Market - Live News